Company profile: InKaryo
1.1 - Company Overview
Company description
- Provider of cytogenetic analysis services.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to InKaryo
Repare Therapeutics
HQ: Canada
Website
- Description: Provider of oncology drug discovery and development targeting synthetic lethality, leveraging the SNIPRx CRISPR-based platform to identify gene pairs and develop targeted cancer therapies. Pipeline includes camonsertib (ATR inhibitor), lunresertib (PKMYT1 inhibitor), and preclinical RP-1664 (PLK4) and RP-3467 (Polθ), with ongoing clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Repare Therapeutics company profile →
Genome Medical
HQ: United States
Website
- Description: Provider of telegenomics technology and services enabling access to genomic-based medicine, including telehealth genetic counseling; Test Plan for test review, authorization, ordering and personalized outreach; a Digital Risk Assessment module; Precision Insights strategic advisory; MCED testing facilitation with clinical action plans; and reproductive genetics counseling and testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genome Medical company profile →
Predicine
HQ: United States
Website
- Description: Provider of genomic profiling tests and algorithms for cancer diagnostics and monitoring, including PredicineATLAS (600-gene NGS with TMB/MSI), PredicineCARE (152-gene cfDNA for treatment selection), PredicineRNA (88-gene cfRNA for fusions/splicing), PredicineHEME (259-gene for hematologic malignancies), PredicineBEACON (MRD tracking), and PredicineWES+ (liquid biopsy exome sequencing for clinical trials).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Predicine company profile →
NantOmics
HQ: United States
Website
- Description: Provider of cloud-based molecular profiling tools for cancer care, including GPS Cancer, a comprehensive test integrating DNA sequencing, RNA sequencing, and proteomics to guide personalized treatment; an integrated panomic approach to detect tumor alterations; and machine vision AI software analyzing digital pathology to identify cancer subtypes and therapy resistance mechanisms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NantOmics company profile →
Isarna Therapeutics
HQ: Germany
Website
- Description: Provider of selective TGF-β inhibitors and antisense oligonucleotide therapies, advancing a pipeline of novel oligonucleotides and combination modalities. Offerings include ISTH0036, an antisense oligonucleotide in Phase 2a for ophthalmic conditions, and therapies targeting TGF-β signaling for fibrotic liver disease, NASH, and various cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Isarna Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for InKaryo
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to InKaryo
2.2 - Growth funds investing in similar companies to InKaryo
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for InKaryo
4.2 - Public trading comparable groups for InKaryo
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →